Uniqure N.v Stock News

LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE ), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington''s disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany. "We are very pleased to expand the clinical development of AMT-130 and to build on our ongoing experience in the Phase I/II clinical trial in the United States," stated Ricardo Dolmetsch, Ph.D., president of research and development at uniQure. "We expect to complete patient enrollment in this European study by the end of the year and to provide safety and target-engagement data from the full 10-patient, low-dose cohort in the U.S. trial in the second quarter of this year." "The Interventional Neurotherapy Center (INC) at Mazowiecki Szpital Bródnowski Hospital is the first and only center in Europe currently performing MRI-guided infusions of gene therapies," said Professor Miroslaw Zabek M.D.

Investors may want to consider the following non-cyclical stocks, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are outperforming the 20-year high-quality m

uniQure: Betting On Hemophilia-B Cure

uniQure N.V. (QURE) shares closed today at 0.5% above its 52 week low of $19.50, giving the company a market cap of $902M. The stock is currently down 5.9% year-to-date, down 48.3% over the past 12 months, and up 224.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 41.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 39.9% The company's stock price performance over the past 12 months lags the peer average by 120.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -98.3% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The heavy selling pressure might have exhausted for uniQure (QURE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts

The heavy selling pressure might have exhausted for uniQure (QURE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in

uniQure (QURE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street analysts predict that uniQure (NASDAQ:QURE) will report earnings of ($0.72) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for uniQures earnings, with the lowest EPS estimate coming in at ($1.09) and the highest estimate coming in at $1.06. uniQure posted earnings per share of ($0.01) in []

uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.

UniQure NV (NASDAQ: QURE ) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington''s disease. AMT-130 was generally well tolerated at the lower dose of 6x1012 vector genomes (vg). There have been no serious adverse events (SAEs) related to AMT-130. Related Link: DSMB Recommends UniQure To Continue Huntington''s Gene Therapy Trial Unchanged . NfL increased as expected following the AMT-130 surgical procedure and returned to baseline. Full story available on Benzinga.com

Shares of uniQure (NASDAQ:QURE) have received a consensus recommendation of Buy from the thirteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year target price among analysts that have []

The stock price of Uniqure NV (NASDAQ: QURE) fell by over 29% today. This is why it happened.

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington's disease.  AMT-130 was generally

~ Treatment was well tolerated with no significant safety issues